Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer

Area of Science:

• Oncology
• Nanotechnology
• Vascular Biology

Background:

• Anti-angiogenic therapy targets tumor vascular endothelial cells (ECs) to inhibit tumor growth.
• Bevacizumab (Avastin) trials demonstrated modest clinical efficiency and potential for acquired resistance.
• Combining anti-angiogenic therapy with drug delivery systems and other treatments shows synergistic effects.

Purpose of the Study:

• Discuss clinical difficulties of traditional anti-angiogenic therapy.
• Highlight applications of anti-angiogenic nanoagents in monotherapies and combination therapies.
• Summarize challenges and perspectives for future anti-angiogenic cancer therapy.

Main Methods:

• Review of clinical difficulties with conventional anti-angiogenic agents.
• Exploration of nanotechnology-based drug delivery for anti-angiogenic therapy.
• Analysis of combination strategies including chemotherapy, radiotherapy, phototherapy, and immunotherapy.

Main Results:

• Traditional anti-angiogenic therapy presents clinical challenges and acquired resistance.
• Anti-angiogenic nanoagents show promise in monotherapy and combination approaches.
• Synergistic effects observed when combining anti-angiogenic therapy with advanced delivery or other modalities.

Conclusions:

• Advanced drug delivery and combination strategies can overcome limitations of anti-angiogenic therapy.
• Anti-angiogenic nanoagents offer a promising new horizon for cancer treatment.
• Further research into challenges and perspectives is crucial for optimizing anti-angiogenic cancer therapy.